atazanavir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
HIV protease inhibitors 254 198904-31-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BMS-232632
  • atazanavir
  • reyataz
  • atazanavir sulphate
  • atazanavir sulfate
An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS. There was some evidence of in vitro activity against SARS-CoV-2, but no clinical trial data was found to support use in the treatment of COVID-19.
  • Molecular weight: 704.87
  • Formula: C38H52N6O7
  • CLOGP: 5.92
  • LIPINSKI: 3
  • HAC: 13
  • HDO: 5
  • TPSA: 171.22
  • ALOGS: -5.33
  • ROTB: 18
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.30 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 7 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 8.11 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 64 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.873 High 0.80
caco2-efflux Caco-2 efflux ratio (BA/AB) 17.989 High 0.80
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 19.454 10^-6 cm/s High 0.80
dh-clint Dog hepatocyte intrinsic clearance 31.261 uL/min/10^6 cells High 0.80
dppb Dog plasma protein binding (% unbound) 7.680 % High 0.80
fcs-ppb Fetal calf serum protein binding (% unbound) 17.750 % High 0.80
herg hERG pIC50 4.686 pIC50 High 0.80
hh-clint Human hepatocyte intrinsic clearance 10.423 uL/min/10^6 cells High 0.80
hlm-clint Human liver microsomal intrinsic clearance 251.189 uL/min/mg protein High 0.80
hppb Human plasma protein binding (% unbound) 12.710 % High 0.80
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK,TGFBR1 19
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 18.281 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 23.714 High 0.80
mh-clint Mouse hepatocyte intrinsic clearance 57.280 High 0.80
mppb Mouse plasma protein binding (% unbound) 4.750 High 0.80
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 51.523 High 0.80
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 10.670 % High 0.80
rat-kpuu-brain Rat brain Kpuu 0.010 % High 1
rh-clint Rat hepatocyte intrinsic clearance 58.884 uL/min/10^6 cells High 0.80
rh-fuinc Rat hepatocyte fraction unbound in incubation 41.170 % High 0.80
rppb Rat plasma protein binding (% unbound) 8.680 % High 0.80
solubility-dd Solubility at pH 7.4 in DMSO 23.281 uM High 0.80

Approvals:

DateAgencyCompanyOrphan
March 2, 2004 EMA
June 20, 2003 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abortion spontaneous 1081.96 29.76 340 8665 53716 90565726
Foetal exposure during pregnancy 980.54 29.76 299 8706 42676 90576766
Maternal exposure during pregnancy 706.64 29.76 439 8566 359624 90259818
Exposure during pregnancy 476.81 29.76 295 8710 238115 90381327
Abortion induced 450.42 29.76 123 8882 11765 90607677
Premature baby 375.62 29.76 127 8878 24950 90594492
Stillbirth 309.92 29.76 83 8922 7360 90612082
Caesarean section 285.68 29.76 96 8909 18481 90600961
Hyperbilirubinaemia 262.61 29.76 84 8921 13852 90605590
Premature delivery 253.15 29.76 107 8898 38655 90580787
Pregnancy 234.21 29.76 117 8888 61930 90557512
Live birth 226.66 29.76 124 8881 78983 90540459
Drug interaction 206.40 29.76 190 8815 276263 90343179
Virologic failure 194.57 29.76 45 8960 2179 90617263
Foetal death 141.20 29.76 59 8946 20664 90598778
Foetal growth restriction 134.40 29.76 46 8959 9334 90610108
Pregnancy on contraceptive 128.29 29.76 29 8976 1266 90618176
Congenital naevus 126.34 29.76 21 8984 169 90619273
Viral mutation identified 120.39 29.76 30 8975 1995 90617447
Jaundice 118.71 29.76 60 8945 32457 90586985
Immune reconstitution inflammatory syndrome 114.70 29.76 38 8967 6981 90612461
Ventricular septal defect 111.79 29.76 35 8970 5372 90614070
Nephrolithiasis 111.02 29.76 66 8939 49019 90570423
Premature rupture of membranes 110.84 29.76 35 8970 5523 90613919
Supernumerary nipple 108.58 29.76 16 8989 51 90619391
Viral load increased 107.44 29.76 26 8979 1530 90617912
Cushing's syndrome 106.85 29.76 22 8983 614 90618828
Renal colic 105.88 29.76 26 8979 1627 90617815
Low set ears 104.98 29.76 19 8986 262 90619180
Acoustic stimulation tests abnormal 102.17 29.76 16 8989 84 90619358
Low birth weight baby 92.58 29.76 35 8970 9432 90610010
Normal newborn 87.87 29.76 44 8961 23318 90596124
Blood bilirubin increased 86.86 29.76 54 8951 43416 90576026
Renal dysplasia 86.74 29.76 17 8988 367 90619075
Blood HIV RNA increased 84.60 29.76 19 8986 805 90618637
Lipodystrophy acquired 82.89 29.76 21 8984 1493 90617949
Twin pregnancy 76.83 29.76 19 8986 1224 90618218
Pre-eclampsia 73.71 29.76 31 8974 11017 90608425
Placenta praevia 73.60 29.76 18 8987 1107 90618335
Patent ductus arteriosus 71.71 29.76 24 8981 4545 90614897
Drug resistance 71.60 29.76 42 8963 30407 90589035
Polydactyly 71.05 29.76 14 8991 311 90619131
Premature labour 68.01 29.76 31 8974 13345 90606097
Spina bifida 67.45 29.76 16 8989 864 90618578
Placental insufficiency 66.49 29.76 18 8987 1657 90617785
Adrenal suppression 65.28 29.76 16 8989 993 90618449
Congenital hydrocephalus 63.89 29.76 12 8993 205 90619237
Blood bilirubin unconjugated increased 61.78 29.76 13 8992 404 90619038
Gestational diabetes 61.72 29.76 27 8978 10555 90608887
Pain 60.02 29.76 13 8992 996328 89623114
Single functional kidney 58.48 29.76 12 8993 329 90619113
Pathogen resistance 58.28 29.76 24 8981 8091 90611351
Oligohydramnios 57.56 29.76 23 8982 7178 90612264
Fanconi syndrome acquired 56.76 29.76 15 8990 1259 90618183
Drug ineffective 55.24 29.76 35 8970 1384263 89235179
Genotype drug resistance test positive 55.19 29.76 12 8993 437 90619005
Trisomy 21 54.95 29.76 12 8993 446 90618996
Trisomy 18 54.91 29.76 10 8995 143 90619299
CD4 lymphocytes decreased 53.88 29.76 15 8990 1532 90617910
Treatment noncompliance 53.56 29.76 43 8962 51684 90567758
Osteonecrosis 53.42 29.76 33 8972 26208 90593234
Renal tubular disorder 50.94 29.76 17 8988 3190 90616252
Polyhydramnios 50.86 29.76 16 8989 2492 90616950
Hydrocephalus 47.10 29.76 19 8986 6075 90613367
Left ventricular dilatation 45.34 29.76 11 8994 654 90618788
Renal aplasia 44.70 29.76 10 8995 416 90619026
Isoimmune haemolytic disease 44.20 29.76 7 8998 40 90619402
Eosinophilia 43.65 29.76 30 8975 28503 90590939
Congenital central nervous system anomaly 43.63 29.76 10 8995 464 90618978
Foetal distress syndrome 43.60 29.76 13 8992 1692 90617750
Ultrasound antenatal screen abnormal 42.97 29.76 8 8997 130 90619312
Amniotic cavity infection 41.67 29.76 12 8993 1384 90618058
Breast disorder 41.31 29.76 14 8991 2753 90616689
Coarctation of the aorta 40.90 29.76 10 8995 614 90618828
Ocular icterus 39.94 29.76 15 8990 3965 90615477
Macrocephaly 39.47 29.76 8 8997 206 90619236
Calculus urinary 39.35 29.76 12 8993 1686 90617756
Ectopic pregnancy 39.14 29.76 14 8991 3227 90616215
Joint swelling 38.69 29.76 3 9002 503297 90116145
Mitochondrial cytopathy 38.23 29.76 8 8997 242 90619200
Microcephaly 37.35 29.76 11 8994 1373 90618069
Hepatitis B DNA increased 37.04 29.76 8 8997 282 90619160
Alpha 1 foetoprotein abnormal 36.24 29.76 6 8999 47 90619395
Maternal drugs affecting foetus 36.18 29.76 15 8990 5140 90614302
Fatigue 36.15 29.76 37 8968 1153986 89465456
Encephalomalacia 31.76 29.76 8 8997 555 90618887
Cholestasis of pregnancy 31.72 29.76 10 8995 1567 90617875
Fall 31.68 29.76 5 9000 481805 90137637
Placental disorder 31.51 29.76 10 8995 1601 90617841
Congenital skin dimples 31.39 29.76 6 8999 113 90619329
Abdominal discomfort 31.28 29.76 5 9000 477323 90142119
Cerebral ventricle dilatation 31.26 29.76 9 8996 1037 90618405
Oesophageal atresia 30.87 29.76 8 8997 622 90618820
Swelling 30.83 29.76 3 9002 419055 90200387
Conduction disorder 30.78 29.76 10 8995 1725 90617717
Subchorionic haematoma 30.42 29.76 6 8999 134 90619308
Renal failure 30.38 29.76 50 8955 130957 90488485
Foetal anaemia 30.33 29.76 6 8999 136 90619306
Dyspnoea 30.18 29.76 26 8979 880929 89738513
Placental chorioangioma 30.10 29.76 4 9001 4 90619438

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 1671.95 18.43 1147 16602 265852 42337734
Depression 1593.18 18.43 818 16931 110545 42493041
Psychiatric decompensation 514.88 18.43 149 17600 4073 42599513
Depression suicidal 488.42 18.43 135 17614 3110 42600476
Tearfulness 478.31 18.43 135 17614 3365 42600221
Lipodystrophy acquired 435.11 18.43 125 17624 3325 42600261
Nephrolithiasis 431.33 18.43 238 17511 36592 42566994
Depressive symptom 421.47 18.43 125 17624 3728 42599858
Hyperbilirubinaemia 404.67 18.43 189 17560 20446 42583140
Foetal exposure during pregnancy 398.75 18.43 247 17502 47064 42556522
Psychomotor skills impaired 372.31 18.43 122 17627 5082 42598504
Loss of personal independence in daily activities 333.28 18.43 225 17524 49591 42553995
Renal colic 329.52 18.43 90 17659 1978 42601608
Paranoia 314.28 18.43 141 17608 13885 42589701
Jaundice 259.76 18.43 168 17581 34421 42569165
Psychotic disorder 249.67 18.43 154 17595 29054 42574532
Renal tubular disorder 219.25 18.43 81 17668 4828 42598758
Suicidal ideation 214.03 18.43 170 17579 47991 42555595
Mitochondrial toxicity 197.91 18.43 64 17685 2551 42601035
Blood bilirubin increased 196.02 18.43 153 17596 42099 42561487
Eyelid ptosis 168.64 18.43 73 17676 6588 42596998
Immune reconstitution inflammatory syndrome 162.64 18.43 81 17668 10062 42593524
Fanconi syndrome acquired 158.03 18.43 51 17698 2019 42601567
Virologic failure 156.89 18.43 60 17689 3934 42599652
Lipoatrophy 127.92 18.43 31 17718 414 42603172
Calculus urinary 120.83 18.43 40 17709 1717 42601869
Psychomotor retardation 120.55 18.43 51 17698 4348 42599238
Ocular icterus 105.58 18.43 42 17707 3059 42600527
Viral mutation identified 92.54 18.43 39 17710 3292 42600294
HIV-associated neurocognitive disorder 88.66 18.43 22 17727 326 42603260
Off label use 87.17 18.43 83 17666 638252 41965334
Blood bilirubin unconjugated increased 86.78 18.43 25 17724 670 42602916
Trisomy 21 86.55 18.43 24 17725 558 42603028
Osteonecrosis 85.76 18.43 63 17686 15802 42587784
Blood HIV RNA increased 85.07 18.43 30 17719 1561 42602025
Premature baby 84.53 18.43 73 17676 23080 42580506
Anxiety 83.83 18.43 165 17584 118395 42485191
Prescribed overdose 80.61 18.43 56 17693 12871 42590715
Viral load increased 79.64 18.43 34 17715 2963 42600623
Drug ineffective 79.15 18.43 88 17661 630109 41973477
Fanconi syndrome 77.88 18.43 29 17720 1765 42601821
Heterotaxia 74.02 18.43 16 17733 123 42603463
Diplopia 72.03 18.43 63 17686 20253 42583333
Cushing's syndrome 71.65 18.43 19 17730 371 42603215
Kaposi's sarcoma 66.49 18.43 21 17728 774 42602812
Single umbilical artery 65.65 18.43 16 17733 219 42603367
CD4 lymphocytes decreased 65.33 18.43 26 17723 1895 42601691
Death 62.15 18.43 63 17686 471122 42132464
Proteinuria 61.63 18.43 61 17688 22922 42580664
Pathogen resistance 60.83 18.43 45 17704 11405 42592181
Cholelithiasis 60.82 18.43 61 17688 23285 42580301
Glycosuria 58.93 18.43 22 17727 1348 42602238
Osteoporosis 56.44 18.43 48 17701 14858 42588728
Pulmonary haemorrhage neonatal 52.24 18.43 9 17740 15 42603571
Ureterolithiasis 48.69 18.43 23 17726 2541 42601045
Chordee 46.13 18.43 10 17739 78 42603508
Hypotension 46.06 18.43 25 17724 257606 42345980
Blood antidiuretic hormone increased 45.12 18.43 9 17740 44 42603542
Disease progression 45.09 18.43 4 17745 143652 42459934
Cortisol decreased 44.61 18.43 18 17731 1360 42602226
Fall 43.03 18.43 22 17727 234498 42369088
Periventricular leukomalacia 42.72 18.43 10 17739 114 42603472
Hypertriglyceridaemia 41.21 18.43 34 17715 10092 42593494
Nephropathy toxic 40.23 18.43 42 17707 16796 42586790
Exposure during pregnancy 39.68 18.43 31 17718 8517 42595069
Hepatitis C 39.12 18.43 33 17716 10100 42593486
Pneumonia 38.94 18.43 73 17676 422076 42181510
Nephrocalcinosis 38.62 18.43 14 17735 789 42602797
Drug resistance 37.68 18.43 58 17691 34190 42569396
Alanine aminotransferase increased 36.85 18.43 100 17649 88306 42515280
Acquired immunodeficiency syndrome 36.67 18.43 12 17737 496 42603090
Ophthalmoplegia 36.53 18.43 18 17731 2182 42601404
HIV wasting syndrome 35.50 18.43 8 17741 76 42603510
Neonatal hyponatraemia 34.43 18.43 8 17741 88 42603498
Dyspnoea 33.81 18.43 85 17664 442536 42161050
Febrile neutropenia 33.19 18.43 18 17731 185685 42417901
CSF HIV escape syndrome 32.88 18.43 9 17740 199 42603387
Foetal chromosome abnormality 32.65 18.43 6 17743 17 42603569
Congenital naevus 32.40 18.43 6 17743 18 42603568
Dysphagia 32.06 18.43 84 17665 72635 42530951
Crystal urine 30.30 18.43 7 17742 75 42603511
Vanishing bile duct syndrome 30.15 18.43 15 17734 1856 42601730
CSF virus identified 29.49 18.43 6 17743 33 42603553
Congenital hydrocephalus 29.48 18.43 8 17741 171 42603415
Adrenal suppression 29.16 18.43 12 17737 953 42602633
White matter lesion 28.78 18.43 12 17737 986 42602600
Trimethylaminuria 28.43 18.43 5 17744 10 42603576
Hepatitis 28.31 18.43 45 17704 27255 42576331
Wrong dose 27.82 18.43 12 17737 1072 42602514
Renal failure 27.77 18.43 126 17623 143600 42459986
Constipation 27.19 18.43 17 17732 162274 42441312
Facial wasting 27.14 18.43 7 17742 122 42603464
Biliary colic 27.00 18.43 12 17737 1152 42602434
Alpha 1 foetoprotein abnormal 27.00 18.43 5 17744 15 42603571
Hepatic cirrhosis 26.96 18.43 37 17712 19665 42583921
Sepsis 26.92 18.43 26 17723 199308 42404278
Blood pressure increased 26.79 18.43 5 17744 101923 42501663
Anomalous pulmonary venous connection 26.68 18.43 7 17742 131 42603455
Enanthema 26.60 18.43 10 17739 625 42602961
Low birth weight baby 25.90 18.43 26 17723 9929 42593657
Hydronephrosis 25.53 18.43 28 17721 11837 42591749
Hypothalamic pituitary adrenal axis suppression 25.32 18.43 8 17741 295 42603291
Product dose omission issue 24.74 18.43 17 17732 154348 42449238
Intestinal malrotation 24.65 18.43 5 17744 27 42603559
Neonatal seizure 24.53 18.43 9 17740 525 42603061
Cystitis noninfective 24.21 18.43 9 17740 545 42603041
Pain 23.72 18.43 41 17708 244807 42358779
Intraventricular haemorrhage neonatal 23.71 18.43 8 17741 364 42603222
Thalassaemia alpha 23.67 18.43 5 17744 34 42603552
Hyperbilirubinaemia neonatal 23.61 18.43 10 17739 854 42602732
Genotype drug resistance test positive 23.48 18.43 11 17738 1193 42602393
Aspartate aminotransferase increased 23.36 18.43 78 17671 77085 42526501
Atrial fibrillation 22.86 18.43 15 17734 139578 42464008
Genitalia external ambiguous 22.85 18.43 7 17742 233 42603353
Cardiac failure 22.81 18.43 8 17741 106848 42496738
Completed suicide 22.80 18.43 6 17743 96459 42507127
Blood lactic acid increased 22.78 18.43 22 17727 8017 42595569
Ventricular septal defect 22.71 18.43 17 17732 4382 42599204
Haemophilic arthropathy 22.35 18.43 7 17742 251 42603335
Renal tubular dysfunction 22.15 18.43 8 17741 446 42603140
Adrenogenital syndrome 22.14 18.43 5 17744 48 42603538
Peripheral motor neuropathy 22.06 18.43 13 17736 2251 42601335
Cough 22.05 18.43 25 17724 178078 42425508
Progressive external ophthalmoplegia 21.82 18.43 11 17738 1400 42602186
Anogenital warts 21.74 18.43 9 17740 726 42602860
Umbilical cord abnormality 21.52 18.43 5 17744 55 42603531
Mitochondrial cytopathy 21.03 18.43 6 17743 155 42603431
Jarisch-Herxheimer reaction 20.97 18.43 9 17740 794 42602792
Heart transplant rejection 20.95 18.43 11 17738 1523 42602063
Cardiac failure congestive 20.85 18.43 5 17744 85597 42517989
Condition aggravated 20.70 18.43 49 17700 260705 42342881
Peripheral swelling 20.61 18.43 6 17743 90264 42513322
Blood triglycerides increased 20.47 18.43 29 17720 15867 42587719
Drug abuse 20.46 18.43 9 17740 104762 42498824
Cranial nerve palsies multiple 20.41 18.43 5 17744 70 42603516
Encephalitis 20.38 18.43 22 17727 9136 42594450
Portal fibrosis 20.33 18.43 7 17742 339 42603247
Acute stress disorder 20.18 18.43 6 17743 180 42603406
Relapsing fever 20.15 18.43 6 17743 181 42603405
Right aortic arch 19.98 18.43 4 17745 20 42603566
Hyperadrenocorticism 19.93 18.43 6 17743 188 42603398
Incorrect route of product administration 19.82 18.43 36 17713 24269 42579317
Congenital hepatomegaly 19.66 18.43 4 17745 22 42603564
Persistent left superior vena cava 19.36 18.43 4 17745 24 42603562
Erythema elevatum diutinum 19.09 18.43 4 17745 26 42603560
Pancreatitis 19.08 18.43 50 17699 43218 42560368
Mycobacterium avium complex infection 18.60 18.43 13 17736 3014 42600572

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 1661.26 19.44 1068 19377 499115 110069739
Depression 915.50 19.44 623 19822 316712 110252142
Abortion spontaneous 896.71 19.44 308 20137 33974 110534880
Psychiatric decompensation 588.70 19.44 149 20296 5616 110563238
Hyperbilirubinaemia 587.98 19.44 219 20226 30452 110538402
Lipodystrophy acquired 567.92 19.44 138 20307 4386 110564468
Depression suicidal 538.98 19.44 134 20311 4690 110564164
Tearfulness 486.80 19.44 135 20310 7260 110561594
Nephrolithiasis 475.81 19.44 236 20209 65976 110502878
Psychomotor skills impaired 437.84 19.44 123 20322 6935 110561919
Maternal exposure during pregnancy 429.77 19.44 364 20081 254519 110314335
Depressive symptom 420.85 19.44 124 20321 8290 110560564
Paranoia 364.72 19.44 142 20303 22232 110546622
Jaundice 355.36 19.44 187 20258 59049 110509805
Abortion induced 348.34 19.44 106 20339 7913 110560941
Renal colic 311.88 19.44 80 20365 3178 110565676
Immune reconstitution inflammatory syndrome 275.14 19.44 106 20339 16120 110552734
Psychotic disorder 275.12 19.44 150 20295 50787 110518067
Virologic failure 274.23 19.44 79 20366 4873 110563981
Stillbirth 267.58 19.44 75 20370 4189 110564665
Loss of personal independence in daily activities 262.17 19.44 219 20226 149801 110419053
Mitochondrial toxicity 249.66 19.44 67 20378 3178 110565676
Viral mutation identified 238.03 19.44 69 20376 4350 110564504
Renal tubular disorder 234.55 19.44 77 20368 7352 110561502
Exposure during pregnancy 229.61 19.44 213 20232 167211 110401643
Suicidal ideation 226.65 19.44 166 20279 93771 110475083
Blood bilirubin increased 215.02 19.44 148 20297 75824 110493030
Caesarean section 201.69 19.44 81 20364 13736 110555118
Fanconi syndrome acquired 188.70 19.44 53 20392 2981 110565873
Premature delivery 181.58 19.44 96 20349 30536 110538318
Eyelid ptosis 180.36 19.44 74 20371 13253 110555601
Viral load increased 169.65 19.44 50 20395 3340 110565514
Pathogen resistance 147.90 19.44 70 20375 17602 110551252
Calculus urinary 142.58 19.44 43 20402 3109 110565745
Cushing's syndrome 140.69 19.44 33 20412 897 110567957
Blood bilirubin unconjugated increased 137.88 19.44 34 20411 1147 110567707
Pregnancy 133.96 19.44 95 20350 50972 110517882
Osteonecrosis 125.40 19.44 78 20367 33663 110535191
Psychomotor retardation 125.31 19.44 49 20396 7743 110561111
Blood HIV RNA increased 117.10 19.44 34 20411 2154 110566700
Drug resistance 116.77 19.44 91 20354 56283 110512571
Pregnancy on contraceptive 112.55 19.44 28 20417 980 110567874
Ocular icterus 111.42 19.44 42 20403 6011 110562843
Foetal exposure during pregnancy 106.08 19.44 43 20402 7462 110561392
Foetal death 99.95 19.44 52 20393 15993 110552861
CD4 lymphocytes decreased 98.62 19.44 32 20413 2942 110565912
Adrenal suppression 98.11 19.44 28 20417 1668 110567186
HIV-associated neurocognitive disorder 97.30 19.44 21 20424 387 110568467
Fanconi syndrome 97.25 19.44 33 20412 3486 110565368
Live birth 92.40 19.44 87 20358 69397 110499457
CSF HIV escape syndrome 88.66 19.44 19 20426 338 110568516
Genotype drug resistance test positive 80.38 19.44 23 20422 1383 110567471
Proteinuria 79.41 19.44 63 20382 39955 110528899
Lipoatrophy 77.80 19.44 19 20426 615 110568239
Drug ineffective 76.50 19.44 102 20343 1520438 109048416
Diplopia 74.78 19.44 62 20383 41832 110527022
Premature rupture of membranes 74.00 19.44 29 20416 4608 110564246
Pain 70.46 19.44 45 20400 954910 109613944
Twin pregnancy 70.02 19.44 19 20426 939 110567915
Renal failure 69.85 19.44 139 20306 226435 110342419
Off label use 65.38 19.44 111 20334 1500074 109068780
Nephropathy toxic 64.93 19.44 48 20397 27430 110541424
Glycosuria 62.37 19.44 22 20423 2608 110566246
Anxiety 60.69 19.44 170 20275 344908 110223946
Placenta praevia 59.20 19.44 16 20429 779 110568075
Hypertriglyceridaemia 56.63 19.44 36 20409 16118 110552736
Cholelithiasis 56.41 19.44 64 20381 63358 110505496
Acute kidney injury 54.45 19.44 247 20198 635183 109933671
Fall 54.05 19.44 22 20423 603460 109965394
Pre-eclampsia 53.77 19.44 28 20417 8622 110560232
Cortisol decreased 53.36 19.44 20 20425 2816 110566038
Joint swelling 53.13 19.44 9 20436 442836 110126018
Treatment noncompliance 52.33 19.44 66 20379 72924 110495930
Osteoporosis 51.98 19.44 72 20373 87080 110481774
Peripheral swelling 51.24 19.44 7 20438 404027 110164827
Abdominal discomfort 49.53 19.44 7 20438 393851 110175003
Mitochondrial cytopathy 49.30 19.44 12 20433 383 110568471
Normal newborn 48.94 19.44 37 20408 21859 110546995
Renal tubular dysfunction 48.38 19.44 14 20431 876 110567978
Ureterolithiasis 48.09 19.44 21 20424 4381 110564473
Swelling 47.17 19.44 5 20440 351036 110217818
Acquired immunodeficiency syndrome 45.31 19.44 11 20434 347 110568507
Hepatitis 44.40 19.44 68 20377 89986 110478868
Infection 44.24 19.44 7 20438 362193 110206661
Renal dysplasia 43.54 19.44 8 20437 61 110568793
Blood antidiuretic hormone increased 42.67 19.44 8 20437 69 110568785
Ophthalmoplegia 42.27 19.44 18 20427 3532 110565322
Polyhydramnios 41.42 19.44 15 20430 1918 110566936
Dyspnoea 40.21 19.44 91 20354 1106781 109462073
Amniotic cavity infection 39.42 19.44 12 20433 895 110567959
Placental insufficiency 39.18 19.44 13 20432 1281 110567573
Secondary adrenocortical insufficiency 38.43 19.44 18 20427 4416 110564438
Premature baby 36.88 19.44 18 20427 4837 110564017
Alanine aminotransferase increased 36.75 19.44 95 20350 183678 110385176
HIV wasting syndrome 36.22 19.44 7 20438 72 110568782
Foetal exposure during delivery 36.13 19.44 6 20439 23 110568831
Nasopharyngitis 35.89 19.44 14 20431 394347 110174507
Spina bifida 35.85 19.44 8 20437 173 110568681
Hepatitis B DNA increased 35.83 19.44 11 20434 844 110568010
Condition aggravated 35.06 19.44 51 20394 734785 109834069
Gestational diabetes 35.05 19.44 20 20425 7369 110561485
Nephrocalcinosis 34.89 19.44 13 20432 1801 110567053
Vanishing bile duct syndrome 34.24 19.44 15 20430 3153 110565701
Renal impairment 34.23 19.44 94 20351 188351 110380503
COVID-19 34.20 19.44 3 20442 245057 110323797
CSF virus identified 33.91 19.44 6 20439 36 110568818
Hypophosphataemia 33.86 19.44 36 20409 33146 110535708
Arthralgia 32.61 19.44 59 20386 779573 109789281
Ergot poisoning 32.38 19.44 7 20438 130 110568724
Dysphagia 32.37 19.44 81 20364 153519 110415335
Hepatitis C 32.05 19.44 23 20422 12550 110556304
Product use issue 31.97 19.44 9 20436 311686 110257168
Blood lactic acid increased 31.58 19.44 25 20420 15796 110553058
Single functional kidney 31.57 19.44 8 20437 302 110568552
Wheezing 31.01 19.44 5 20440 255225 110313629
Prescribed overdose 30.97 19.44 57 20388 87524 110481330
Renal aplasia 30.87 19.44 7 20438 163 110568691
Mycobacterium avium complex infection 30.85 19.44 17 20428 5860 110562994
Acute HIV infection 30.76 19.44 6 20439 65 110568789
Progressive external ophthalmoplegia 30.35 19.44 11 20434 1409 110567445
Alopecia 29.95 19.44 15 20430 364738 110204116
Placental disorder 29.89 19.44 10 20435 1011 110567843
Pericarditis 29.73 19.44 3 20442 219111 110349743
Hypothalamic pituitary adrenal axis suppression 29.54 19.44 9 20436 673 110568181
Kaposi's sarcoma 29.28 19.44 9 20436 693 110568161
Constipation 28.95 19.44 15 20430 357771 110211083
Cough 28.53 19.44 26 20419 461615 110107239
Syphilis 28.42 19.44 9 20436 765 110568089
Tubulointerstitial nephritis 28.19 19.44 42 20403 54242 110514612
Blood creatinine increased 28.16 19.44 86 20359 182803 110386051
Placental chorioangioma 27.61 19.44 4 20441 4 110568850
Febrile neutropenia 27.59 19.44 12 20433 316755 110252099
Blood corticotrophin decreased 27.59 19.44 9 20436 841 110568013
Crystal urine 27.53 19.44 6 20439 116 110568738
Drug intolerance 27.45 19.44 21 20424 406491 110162363
Hypotension 27.35 19.44 34 20411 523815 110045039
Bilirubin conjugated increased 27.27 19.44 16 20429 6208 110562646
Subchorionic haematoma 27.15 19.44 6 20439 124 110568730
Disease progression 27.05 19.44 6 20439 244028 110324826
Musculoskeletal stiffness 27.04 19.44 9 20436 279813 110289041
Wrong dose 26.88 19.44 12 20433 2637 110566217
Drug hypersensitivity 26.40 19.44 27 20418 454063 110114791
Premature labour 26.22 19.44 18 20427 9154 110559700
Alpha 1 foetoprotein abnormal 25.91 19.44 5 20440 51 110568803
Encephalitis 25.82 19.44 24 20421 18815 110550039
Encephalitis viral 25.42 19.44 12 20433 2995 110565859
Cholestasis 25.39 19.44 44 20401 64474 110504380
Pneumonia 25.06 19.44 81 20364 876633 109692221
Lower respiratory tract infection 24.96 19.44 7 20438 243099 110325755
Toxic skin eruption 24.86 19.44 28 20417 27487 110541367
Conduction disorder 24.84 19.44 13 20432 4042 110564812
Peripheral motor neuropathy 24.75 19.44 13 20432 4073 110564781
Inappropriate schedule of product administration 24.71 19.44 4 20441 203633 110365221
Aspartate aminotransferase increased 24.43 19.44 75 20370 159861 110408993
Jarisch-Herxheimer reaction 24.43 19.44 9 20436 1208 110567646
Cholestasis of pregnancy 24.09 19.44 9 20436 1256 110567598
Congenital hydrocephalus 24.01 19.44 5 20440 77 110568777
Hydronephrosis 23.94 19.44 24 20421 20641 110548213
Stomatitis 23.91 19.44 10 20435 270232 110298622
Product dose omission issue 23.87 19.44 15 20430 321767 110247087
Erythema elevatum diutinum 23.76 19.44 4 20441 17 110568837
Osteoarthritis 23.52 19.44 3 20442 182620 110386234
Acute myocardial infarction 22.95 19.44 49 20396 83728 110485126
C-reactive protein increased 22.89 19.44 6 20439 217913 110350941
Renal tubular necrosis 22.54 19.44 28 20417 30447 110538407
ACTH stimulation test abnormal 22.47 19.44 4 20441 25 110568829
Discomfort 22.39 19.44 6 20439 214701 110354153
Lipohypertrophy 22.28 19.44 8 20437 998 110567856
Oligohydramnios 22.20 19.44 12 20433 3982 110564872
Myocardial infarction 22.19 19.44 82 20363 192001 110376853
Ectopic pregnancy 22.02 19.44 10 20435 2287 110566567
Death 21.79 19.44 62 20383 698807 109870047
Hyperproteinaemia 21.78 19.44 6 20439 314 110568540
Retinal toxicity 21.72 19.44 9 20436 1650 110567204
Myoglobin blood increased 21.55 19.44 12 20433 4220 110564634
Enanthema 21.35 19.44 8 20437 1126 110567728
Placental infarction 21.35 19.44 5 20440 135 110568719
Hypersensitivity 21.31 19.44 26 20419 403972 110164882
Gynaecomastia 21.13 19.44 16 20429 9474 110559380
Portal fibrosis 21.02 19.44 7 20438 698 110568156
Arthritis 21.00 19.44 3 20442 167583 110401271
Hypercapnia 20.92 19.44 17 20428 11142 110557712
Inflammation 20.92 19.44 5 20440 193233 110375621
Depressed mood 20.77 19.44 39 20406 60770 110508084
Blood pressure increased 20.65 19.44 11 20434 258362 110310492
Seborrhoeic dermatitis 20.45 19.44 10 20435 2697 110566157
Cytomegalovirus chorioretinitis 20.41 19.44 14 20431 7114 110561740
Type 2 diabetes mellitus 20.37 19.44 4 20441 177228 110391626
Pain in extremity 20.21 19.44 37 20408 487081 110081773
Labelled drug-drug interaction medication error 20.21 19.44 26 20419 29276 110539578
Haemolytic anaemia 20.12 19.44 22 20423 20898 110547956
Relapsing fever 19.52 19.44 6 20439 462 110568392
Adrenal insufficiency 19.48 19.44 31 20414 42359 110526495

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AE08 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Protease inhibitors
ATC J05AR15 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR23 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
FDA MoA N0000000246 HIV Protease Inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
MeSH PA D017320 HIV Protease Inhibitors
MeSH PA D019380 Anti-HIV Agents
FDA EPC N0000175889 Protease Inhibitor
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000187062 Cytochrome P450 2C8 Inhibitors
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors
FDA MoA N0000191269 UDP Glucuronosyltransferases Inhibitors
FDA MoA N0000191272 UGT1A1 Inhibitors
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35660 HIV protease inhibitor
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:64946 anti-HIV agent

Related Drugs by ATC class:

J05AE Protease inhibitors 10 drugs
amprenavirdarunavirensitrelvirfosamprenavirindinavirnelfinavirnirmatrelvirritonavirsaquinavirtipranavir
J05AR Antivirals for treatment of HIV infections, combinations 19 drugs
abacavirbictegravircobicistatdarunavirdolutegravirdoravirineefavirenzelvitegraviremtricitabinelamivudinelopinavirnevirapine show all 19 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Prevention of HIV Infection after Exposure off-label use
Hyperbilirubinemia contraindication 14783006 DOID:2741
Hepatic failure contraindication 59927004
Chronic type B viral hepatitis contraindication 61977001
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Hemophilia contraindication 90935002
Lactic acidosis contraindication 91273001 DOID:3650
Kidney stone contraindication 95570007
Chronic hepatitis C contraindication 128302006
Liver function tests abnormal contraindication 166603001
Atrioventricular block contraindication 233917008 DOID:0050820
Disease of liver contraindication 235856003 DOID:409
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.91 acidic
pKa2 11.57 acidic
pKa3 4.94 Basic
pKa4 1.0 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 300MG BASE;150MG EVOTAZ BRISTOL N206353 Jan. 29, 2015 RX TABLET ORAL 8148374 Sept. 3, 2029 TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Multidrug resistance protein 1 Transporter IC50 4.17 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter IC50 4.16 CHEMBL
Cytochrome P450 2C9 Enzyme Ki 4.92 WOMBAT-PK
Cytochrome P450 1A2 Enzyme Ki 4.92 WOMBAT-PK
UDP-glucuronosyltransferase 1-1 Enzyme Ki 5.72 WOMBAT-PK
Cytochrome P450 3A4 Enzyme Ki 5.63 WOMBAT-PK
Pol polyprotein Enzyme INHIBITOR Ki 9.62 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein Ki 8.58 WOMBAT-PK
Reverse transcriptase/RNaseH Enzyme IC50 7.59 CHEMBL
Protease Enzyme IC50 8.40 CHEMBL
Replicase polyprotein 1ab Enzyme Ki 6.15 CHEMBL
Protease Enzyme Ki 10.27 CHEMBL
Protease Enzyme Ki 10.12 CHEMBL

External reference:

IDSource
4024316 VUID
N0000022320 NUI
D01276 KEGG_DRUG
229975-97-7 SECONDARY_CAS_RN
343047 RXNORM
C1176383 UMLSCUI
CHEBI:37924 CHEBI
DR7 PDB_CHEM_ID
CHEMBL1163 ChEMBL_ID
CHEMBL1200678 ChEMBL_ID
D000069446 MESH_DESCRIPTOR_UI
DB01072 DRUGBANK_ID
11138 IUPHAR_LIGAND_ID
8181 INN_ID
QZU4H47A3S UNII
148192 PUBCHEM_CID
17380 MMSL
267545 MMSL
30601 MMSL
46998 MMSL
d04882 MMSL
4021397 VANDF
4024316 VANDF
000306 NDDF
000539 NDDF
404838006 SNOMEDCT_US
413591007 SNOMEDCT_US
413592000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 0003-3622 CAPSULE, GELATIN COATED 300 mg ORAL NDA 29 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 0003-3624 CAPSULE, GELATIN COATED 150 mg ORAL NDA 29 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 0003-3631 CAPSULE, GELATIN COATED 200 mg ORAL NDA 29 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 0003-3638 POWDER 50 mg ORAL NDA 29 sections
EVOTAZ HUMAN PRESCRIPTION DRUG LABEL 2 0003-3641 TABLET 300 mg ORAL NDA 30 sections
Atazanavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5526 CAPSULE 150 mg ORAL ANDA 28 sections
Atazanavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5527 CAPSULE 200 mg ORAL ANDA 28 sections
Atazanavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5528 CAPSULE 300 mg ORAL ANDA 28 sections
Atazanavir HUMAN PRESCRIPTION DRUG LABEL 1 31722-653 CAPSULE 150 mg ORAL ANDA 26 sections
Atazanavir HUMAN PRESCRIPTION DRUG LABEL 1 31722-654 CAPSULE 200 mg ORAL ANDA 26 sections
Atazanavir HUMAN PRESCRIPTION DRUG LABEL 1 31722-655 CAPSULE 300 mg ORAL ANDA 26 sections
Atazanavir Human Prescription Drug Label 1 42385-920 CAPSULE 150 mg ORAL ANDA 27 sections
Atazanavir Human Prescription Drug Label 1 42385-921 CAPSULE 200 mg ORAL ANDA 27 sections
Atazanavir Human Prescription Drug Label 1 42385-922 CAPSULE 300 mg ORAL ANDA 27 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 54868-4854 CAPSULE, GELATIN COATED 200 mg ORAL NDA 27 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 54868-4857 CAPSULE, GELATIN COATED 150 mg ORAL NDA 27 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 54868-5838 CAPSULE, GELATIN COATED 300 mg ORAL NDA 27 sections
Atazanavir Sulfate Human Prescription Drug Label 1 65862-710 CAPSULE 100 mg ORAL ANDA 27 sections
Atazanavir Sulfate Human Prescription Drug Label 1 65862-711 CAPSULE 150 mg ORAL ANDA 27 sections
Atazanavir Sulfate Human Prescription Drug Label 1 65862-712 CAPSULE 200 mg ORAL ANDA 27 sections
Atazanavir Sulfate Human Prescription Drug Label 1 65862-713 CAPSULE 300 mg ORAL ANDA 27 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 67296-1236 CAPSULE, GELATIN COATED 300 mg ORAL NDA 18 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 69189-3624 CAPSULE, GELATIN COATED 150 mg ORAL NDA 28 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 69189-3631 CAPSULE, GELATIN COATED 200 mg ORAL NDA 28 sections
Atazanavir HUMAN PRESCRIPTION DRUG LABEL 1 69238-1135 CAPSULE 100 mg ORAL ANDA 27 sections
Atazanavir HUMAN PRESCRIPTION DRUG LABEL 1 69238-1136 CAPSULE 150 mg ORAL ANDA 27 sections
Atazanavir HUMAN PRESCRIPTION DRUG LABEL 1 69238-1137 CAPSULE 200 mg ORAL ANDA 27 sections
Atazanavir HUMAN PRESCRIPTION DRUG LABEL 1 69238-1138 CAPSULE 300 mg ORAL ANDA 27 sections